Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Caricain, historically referred to as Papaya peptidase A, is a highly basic cysteine protease isolated from the latex of the papaya plant (Carica papaya). It is a prominent member of the C1 family of peptidases (papain-like) and is one of the most abundant enzymes in papaya latex, alongside papain and chymopapain. Caricain is characterized by its broad proteolytic activity and a unique ability to efficiently cleave peptide bonds involving proline and glutamine residues. This specific activity makes it a valuable therapeutic agent for the degradation of immunogenic gluten peptides, which are responsible for triggering inflammatory immune responses in individuals with celiac disease. Beyond its role in digestive health, caricain is utilized in topical pharmaceutical preparations for the debridement of necrotic tissue in chronic wounds and ulcers. While it is used as a therapeutic enzyme (e.g., in the supplement GluteGuard), its application requires caution due to potential cross-reactivity in individuals with latex allergies and possible interactions with anticoagulant therapies.
Enzymatic hydrolysis of peptide bonds; specifically targets and neutralizes immunogenic proline- and glutamine-rich sequences in gluten to prevent the activation of T-cells in the intestinal mucosa.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Caricain.